Ion Channels and Cancer {#s1}
=======================

Ion channels are critical regulators of cellular homeostasis in excitable and non-excitable cells, regulating vital physiological processes, such as electrical signal transmission, gene expression, cell signaling pathways, hormonal secretion, learning, and memory ([@B6]). During oncogenic transformation, cancer cells acquire aberrant characteristics with respect to their normal counterparts, which represent the core of cancer hallmarks, such as self-sustained proliferation, tumor progression, angiogenesis, metastasis, and apoptosis resistance ([@B6]; [@B76]). Many genes encoding ion channels are targets of oncogenic transformation, as previously reported ([@B76]). In turn, these gene products contribute to the development of one or more cancer hallmarks, promoting the transition to a more aggressive cancer phenotype; this is exemplified by the positive correlation between ion channel overexpression and functional dysregulation with tumor progression, invasion, and metastasis ([@B57]; [@B76]). The amount of evidence showcasing abnormal ion channel activity linked to carcinogenesis, cancer migration, and invasion has led to consideration of cancer as a channelopathy ([@B57]; [@B76]).

In cancer, the expression changes of ion channels can be related to early diagnosis, prediction of disease aggressiveness, or as markers that allow monitoring of the response to treatment ([@B53]; [@B48]). Different ion channel subfamilies have been associated with a great variety of cancers from different histological origins and even with particular stages of cancer initiation and progression ([@B79]; [@B48]).

In the present article, we focus on voltage-dependent K^+^- and Na^+^-channels as these are the main targets of scorpion venom in prey capture and self-defense behaviors ([@B77]).

K^+^-Channels in Cancer {#s2}
=======================

K^+^-channels control K^+^ permeability, and play crucial roles in both excitable and non-excitable cells ([@B50]). Voltage-dependent K^+^-channels constitute the largest and most diverse group of voltage-gated ion channels expressed in cells and comprise a pore-forming subunit (K~V~α subunit) that may associate with auxiliary K~V~β subunits ([@B91]; [@B50]). The K~V~β subunits modify ion channel function and/or localization and increase the diversity of physiological roles associated with these ion channels, with implications in health and disease ([@B91]; [@B86]). The scientific literature shows a considerable amount of information indicating the role of K^+^-channels in cell proliferation, cancer progression ([@B96]; [@B70]), and migration ([@B19]), and at least four different mechanisms have been proposed ([**Figure 1**](#f1){ref-type="fig"}), and discussed in-depth in recent dedicated reviews ([@B41]; [@B72]).

![The global effect of scorpion toxins on cancer-related voltage-gated K^+^/Na^+^-channels. An "activation signal" (green) indicates the pathological feature of ion channel activity in the context of cancer development. An "inhibition signal" (red) indicates inhibitory action of scorpion toxins, meaning cancer-hallmark inhibition.](fphar-11-00913-g001){#f1}

In cancer cells, there are significant alterations in the expression of K^+^-channels, which is manifested not only by the increase in their total expression, but also in the relative proportion of their different subtypes ([@B45]; [@B100]). The most prominent ion channel subfamilies present in primary tumors and metastases include Kv, Ether-à-go-go (EAG), and K~Ca~ ([@B91]; [@B50]). Kv10.1, Kv11.1, K~Ca~1.1, and Kv1.3 are the most investigated ion channels, due to their cancer hallmark-related properties. Their implication in preclinical and clinical behavior related to different cancer stages raises them as potential targets for therapy ([**Table 1**](#T1){ref-type="table"}) ([@B23]; [@B76]).

###### 

Main characteristics of the most studied cancer-related K^+^/Na^+^-channels and their recognized modulating toxins.

  Ion channel                               Characteristics                                                                  Localization                                                                                                              Expression level                                                                                                                Biological Activity\*                                                             Scorpion toxin modulators    Ref                                                                                                                                                                                                                                                                                                                                                                                   
  ----------------------------------------- -------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------- ---------------------------- --------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------- ----------------------------------------------------- ----------------------------------
  K~V~11.1                                  Voltage-dependent activation-inactivation/rapid delayed rectifier                Colon (smooth muscle), pancreas, uterus, kidney, blood, brain, heart                                                      Leukemia, ovarian, lung, breast, colon, gastric, brain, skin, prostate                                                          Low expression                                                                    Overexpression               Action potential repolarization (heart), firing frequency and hormone release (endocrine cells), excitability (CNS)   Cell cycle, cell proliferation, apoptosis, migration, invasion                                                                                CsEKerg1                                                    ([@B44]; [@B5]; [@B25]; [@B38])                       
  K~V~10.1                                  Voltage-gated non-inactivating delayed rectifier channel/Calmodulin inhibition   Hypothalamus, hippocampus, cerebral cortex, cerebellum, olfactory nerve                                                   Cervix, lung, breast, colon, ovarian, neuroblastoma, liver, prostate, glioma, gastric, head and neck, squamous cell carcinoma   Low expression                                                                    Overexpression               Activation of? excitable cells, signal transduction, hormone secretion regulation, intracellular osmoregulation       Ion flux-independent mechanism for migration, cell cycle G1-G2/M progression, intracellular pathways, cell proliferation, tumor progression   κ-Hefutoxin 1                                               ([@B62]; [@B70]; [@B11]; [@B94])                      
  K~V~1.3                                   K~V~1.3 (cell membrane)                                                          Voltage-dependent activation-inactivation/delayed rectifier channel                                                       Hypothalamus, olfactory bulb, immune cells, kidney, colon                                                                       Breast, colon, smooth muscle, skeletal muscle, lymph node, B cells                Low expression               Overexpression                                                                                                        Resting membrane potential setting, signal transduction, cell proliferation, volume regulation                                                Proliferation through driving force for Ca^2+^, migration   KAaH1, KAaH2, charybdotoxin, margatoxin, maurotoxin   ([@B71]; [@B55]; [@B92]; [@B85])
  mK~V~1.3 (inner mitochondrial membrane)   Voltage dependent activation-inactivation                                        Overexpression/Low expression in apoptotic resistant cancers                                                              Mitochondrial membrane potential regulation                                                                                     Apoptosis, ROS production, cell proliferation, intracellular signaling pathways                                ([@B55]; [@B17])                                                                                                                                                                                                                                                                                                                                                                      
  K~V~1.1                                   Voltage-dependent activation-inactivation                                        Central and Peripheral Nervous Systems (hippocampus, cerebellum, neocortex, peripheral nerves)                            Glioblastoma, neuroblastoma, breast, colon adenocarcinoma, lung, cervix                                                         Low expression                                                                    Overexpression               Control of firing frequency, regulate action potential repolarization, regulate neurotransmitter release              Tumor progression, mitochondrial metabolism, migration                                                                                        KAaH1, KAaH2                                                ([@B54]; [@B58]; [@B26])                              
  K~Ca~1.1                                  Voltage-dependent activation/Ca^2+^-modulated                                    skeletal muscles, nervous system, epithelium endocrine/exocrine glands, endothelial vascular cells, smooth muscle cells   Somatostatinoma, endometrial, prostate, pituitary, breast, glioblastoma, neuroblastoma                                          Low expression                                                                    Overexpression               Modulation of calcium-signaling processes                                                                             ERK1/2 signaling, proliferation, migration, metastasis, apoptosis                                                                             Iberiotoxin, charybdotoxin                                  ([@B69]; [@B24]; [@B34]; [@B56])                      
  nNaV1.5                                   Voltage-dependent activation--inactivation                                       Skeletal muscle, heart                                                                                                    Breast                                                                                                                          Adult variant (NaV1.5)                                                            Neonatal variant (nNaV1.5)   Action potential generation and propagation                                                                           Migration, invasion, metastasis                                                                                                               unknown                                                     ([@B32]; [@B65]; [@B66]; [@B98]; [@B31])              
  NaV1.6                                    Voltage-dependent activation--inactivation                                       CNS neurons                                                                                                               Cervix, colorectal, astrocytoma                                                                                                 Low expression                                                                    Overexpression               Action potential generation and propagation                                                                           Migration, invasion, metastasis                                                                                                               Cn2, AaHIV                                                  ([@B59]; [@B39])                                      
  NaV1.7                                    Voltage-dependent activation--inactivation                                       PNS neurons, adrenal gland, endocrine pancreatic cells                                                                    Prostate, lung, gastrointestinal tract                                                                                          Low expression                                                                    Overexpression               Action potential generation and propagation                                                                           Migration, invasion, metastasis                                                                                                               unknown                                                     ([@B12]; [@B87]; [@B97]; [@B18])                      

\*Referred to both positive and negative correlation respect to ion channel-regulated physiological and biological activity.

K~V~11.1 (also known as the human Ether-à-go-go (hERG) channel) is probably the most studied ion channel in the EAG subfamily. In normal healthy tissues, its expression is usually low. In contrast, this ion channel is expressed in a higher proportion in leukemia, ovarian, lung, and breast cancer cells, among others ([@B44]). K~V~11.1 channels have notable participation in the cell cycle and appear as regulators of apoptosis and cell proliferation in cancer cells ([@B88]; [@B5]). In the heart, Kv11.1 is key for cardiac repolarization and therefore, its off-target inhibition induces long QT syndrome. Thus, safety pharmacological studies include K~V~11.1 channel assays as the primary test, decreasing its practical impact as an anticancer therapy-related target ([@B38]).

K~V~10.1 channel is selectively expressed in brain areas ([**Table 1**](#T1){ref-type="table"}). However, this channel is overexpressed in more than 70% of tumors and in cancer cell lines from the cervix, lung, breast, ovary, neuroblast, liver, prostate, glial cells, and gastrointestinal tract ([@B62]; [@B94]). Moreover, its crucial role in tumorigenesis, cell signaling, cell cycle, and tumor growth has been recognized ([@B70]). Different experimental approaches have demonstrated the relationship between K~V~10.1 channel blockage and anticancer effects, including induction of apoptosis, inhibition of cell proliferation, and delay in tumor growth ([@B11]), suggesting that this channel is a promising candidate as a tumor and therapeutic marker in oncology.

K~Ca~1.1 channel is ubiquitously expressed in human tissues such as skeletal muscle and the nervous system, with the exception of cardiac myocytes. K~Ca~1.1 channels regulate calcium influx into cells and thereby modulate Ca^2+^-signaling processes ([@B24]). This channel is overexpressed in cancer cell lines from prostate, glia, breast, pancreas, and endometrium ([**Table 1**](#T1){ref-type="table"}) ([@B33]; [@B34]; [@B49]; [@B56]; [@B67]). In the prostate, K~Ca~1.1 channel overexpression regulates proliferation and migration ([@B34]) and in breast cancer, its overexpression has been associated with advanced tumor stage, high tumor cell proliferation, and poor prognosis ([@B69]).

K~V~1.3 channel is mostly expressed in neurons and immune cells ([@B71]). It is located at the plasma membrane, sets the resting membrane potential (RMP) and regulates cell proliferation and cell volume. Furthermore, this channel is also located in the inner mitochondrial membrane (mK~V~1.3), where it plays a role in apoptotic signaling ([@B90]) ([**Table 1**](#T1){ref-type="table"}). Overexpression of K~V~1.3 channels is observed in breast, colon, smooth muscle, skeletal muscle, and lymph node cancers ([@B89]; [@B90]). Its plasma membrane expression is associated with controlling cell proliferation by inducing a transitory hyperpolarization necessary to augment the driving force for Ca^2+^ influx during G1/S progression ([@B85]). Moreover, mK~V~1.3 channels play a role in drug-induced apoptosis by mechanisms that sensitize cancer cells ([@B71]). The potential role of K~V~1.3 channels as cancer therapy targets has been recently evidenced in *in vitro* and *in vivo* experimental models of glioblastoma, melanoma, and pancreatic adenocarcinoma, where mK~V~1.3 inhibition induces apoptotic cell death *in vitro* ([@B55]; [@B92]; [@B17]). All these pieces of evidence promoted K~V~1.3 channels as attractive potential molecular targets in both cancer diagnostics and therapy ([@B23]; [@B76]).

Notwithstanding that the ion channels mentioned above represent some of the most prominent ones in cancer; other voltage-gated ion channels linked to cancer proliferation and progression are upregulated in some tumors and have been described in dedicated reviews ([@B41]; [@B86]).

Na^+^-Channels in Cancer {#s3}
========================

Voltage-dependent sodium channels (VGSC) are transmembrane proteins that are generally expressed in excitable cells, although they are also found, to a limited extent, in non-excitable cells ([@B14]; [@B35]). There are nine pore-forming α-subunits of sodium channels, Na~V~1.1-Na~V~1.9, encoded by the genes SCN1A-SCN11A. The pore-forming α-subunit comprises four highly similar transmembrane domains (I-IV), each composed of six transmembrane segments (S1--S6). The first four transmembrane segments of each domain constitute the voltage sensor domain, and the last two form the pore domain ([@B14]). The α-subunit properties can be modulated in a subtype-specific manner, by association with one or more than one smaller auxiliary β-subunit (Na~V~β~1--4~); conferring tissue-specific expression patterns, varying voltage dependent activation and inactivation, and increasing functional channel density at the plasma membrane ([@B15]).

The oncogenic transformation of VGSC can contribute to the development of one or more cancer hallmarks, promoting the transition to more aggressive cancer phenotypes, as previously reported ([@B76]); this is particularly exemplified by the positive correlation between VGSC overexpression and functional dysregulation with invasion/migration and metastatic potential ([@B3]; [@B31]; [@B61]) ([**Table 1**](#T1){ref-type="table"}).

Proliferating and cancer cells show a RMP between -10 to -50 mV, compared to normal and non-proliferating cells (-50 to -90 mV) ([@B99]). This RMP range fits with the window current range for VGSC, meaning that although the majority of VGSCs will be inactivated, the small percentage of non-inactivated channels will lead to a persistent Na^+^-current, increasing the \[Na\]~i~ ([@B99]). The augmented intracellular Na^+^ concentration leads to an increased intracellular Ca^2+^ concentration, either by promoting the reverse mode of the Na^+^/Ca^2+^ exchanger (NCX) or by inducing plasma membrane depolarization and consequent activation of voltage-sensitive Ca^2+^ channels (VGCC) ([@B73]; [@B82]). Both mechanisms, driven directly or indirectly by VGSC, might be considered relevant for cancer migration and invasion. However, there are very few reports providing experimental evidence about the functional link between VGSC, NCX, and VGCC ([@B8]; [@B4]; [@B81]) and this aspect needs broader investigation.

A hallmark of a tumor´s extracellular space is a more acidic environment than in normal healthy tissues (pH 6.2--6.8 instead of pH 7.2--7.4), as a consequence of the predominant glycolytic metabolism of cancer cells; this particular extracellular environment enhances the degradation of the extracellular matrix by favoring Cathepsin B and S activation, and thus, promotes cell migration ([@B8]; [@B4]). This extracellular acidification is dependent on Na^+^/H^+^ exchanger 1 (NHE1), which in turn depends on the \[Na^+^\] transmembrane gradient ([@B8]; [@B4]). Given the increased \[Na\]~i~, a reduced NHE1 activity should be expected; however, two hypotheses have been suggested to explain this apparent contradiction. i) that these channels allosterically regulate NHE1 by inducing a higher rate of H^+^ extrusion at neutral pHi ranges, and ii) that the expression of VGSC in late endosome vesicles is responsible for the extra-acidification of these vesicles ([@B8]; [@B4]). In this last scenario, the extracellular acidic environment would be a consequence of vesicle release.

Tetrodotoxin (TTX) is a toxin, mainly associated with fishes of the *Tetraodontidae* family, that specifically blocks a subgroup of VGSCs and inhibits the migration and invasion of cancer cells, indicating that cell motility requires Na^+^-channel activity ([@B65]) a feature mainly associated with overexpression of the neonatal variants of Na~V~1.5 (nNa~V~1.5), Na~V~1.6, and Na~V~1.7 ([@B82]; [@B61]).

nNa~V~1.5 overexpression was initially identified in the metastatic human breast cancer cell line MDA-MB-231 and breast biopsy samples ([**Table 1**](#T1){ref-type="table"}) ([@B98]). Later, the same positive correlation was found between the expression of nNa~V~1.5 channels and the high invasive potential of cancer cells from diverse histological origins ([@B31]), suggesting that the overexpression of nNa~V~1.5 channel is necessary and sufficient to increase the metastatic potential of cancer cells ([@B66]).

Na~V~1.6 is overexpressed in cervical cancer biopsies, cancer cell lines, and primary cultures positive for the human papillomavirus ([**Table 1**](#T1){ref-type="table"}). In these cases, a Na~V~1.6 splice variant with preferential cytoplasmatic localization is expressed ([@B59]). Overexpression of Na~V~1.6 protein is associated with invasive status in cervical cancer and low-grade astrocytoma, mediated through increased MMP-2 activity ([@B59]; [@B39]).

Na~V~1.7 is ectopically expressed in particular types of cancers ([**Table 1**](#T1){ref-type="table"}) ([@B12]; [@B97]; [@B18]). In gastric cancer, this channel is associated with poor patient outcomes by promoting cell invasion through the modulation of H^+^ efflux ([@B97]). In rat prostate cancer, Na~V~1.7 channel activity promotes the activation of p38/NF-κβ, and Rho GTPase signaling pathways as a linking node for controlling cellular motility, cell adhesion, and vesicular trafficking ([@B18]). In non-small cell lung cancer, the Na~V~1.7 channel is overexpressed in metastatic cells by more than 60% when compared to their non-metastatic counterparts ([@B12]).

Independent of their function as auxiliary subunits, Na~V~β~1-3~ are overexpressed in different cancers and have been associated with increased cellular motility, invasion, and metastasis ([@B68]; [@B10]). Additionally, Na~V~β~1~ has been linked to tumor growth, increase of vascular endothelial growth factor secretion, and angiogenesis ([@B68]; [@B10]). In contrast, Na~V~β~3~ functions as a tumor suppressor by inducing p53-dependent apoptosis when overexpressed ([@B10]). Thus, the Na~V~β-subunits are interesting and poorly explored potential targets for cancer therapy, needing an in-depth investigation to identify their complete clinical and physiopathological relevance.

Overall, VGSCs and Na~V~β are up-regulated in numerous types of metastatic cancer cells and play important roles in regulating cell migration and invasion in solid tumors. Therefore, they can be considered as key regulators of cancer development and the metastatic cascade ([@B61]). The noncanonical activity of VGSC that regulates other cancer hallmarks (*i.e.*, cell proliferation) is scarcely understood and needs to be investigated with more detail ([@B9]).

Scorpion Venom and Their Toxins in Cancer {#s4}
=========================================

Worldwide, there are more than 2,200 scorpion species, grouped in 19 families ([@B95]). The scorpion venom is a complex mixture containing a great variety of proteins with molecular weights between 3 kDa and 90 kDa, which constitute most of the components. The main biological activity of the scorpion venom is due to the presence of low molecular weight peptide toxins of basic nature, which are highly cross-linked (3--4 disulfide bridges) ([@B77]; [@B51]). These peptides exhibit different pharmacological and toxicological activities ([@B77]; [@B51]). Until now, only a few scorpion species have been experimentally tested as anticancer agents, mainly for cancer cells from solid tumors and to a lesser extent, for hematopoietic cancers ([@B80]).

In only two cases (*B. martensii* and *R. junceus*), the scientific results correlate with the experiences in traditional medicine and with the low toxicity recognized in toxicological experiments in mice ([@B93]; [@B29]; [@B30]). The anticancer effect of *B. martensii* scorpion venom has been tested successfully against human glioma U251-MG by using rodent xenograft models ([@B93]). Likewise, *in vivo* toxicological studies have been carried out, using *R. junceus* venom administered through intraperitoneal (10 mg/kg) or oral (2,000 mg/kg) routes, and toxic effects have not been observed ([@B37]; [@B52]). Pharmacokinetic and biodistribution studies carried out on breast tumor-bearing mice administered with a single dose (12.5 mg/kg), by intravenous or oral routes, showed that medium residence time (MRT) of venom in tumor tissue was higher than in the remaining organs tested, suggesting a high selectivity for tumor tissue, adding to their antitumor effect ([@B29]). Additionally, breast tumor-bearing mice injected intraperitoneally with ten consecutive doses of *R. junceus* venom (3.2 mg/kg), showed reduced tumor progression and reduction of Ki67 and CD31 tumor markers, confirming its anticancer potential ([@B30]). Two additional scorpion species, *Androctonus amoreuxi* ([@B83]) and *Leiurus quinquestriatus* ([@B2]), have been tested with some favorable *in vivo* anticancer effects, even though both are two of the most dangerous species ([@B95]). These overall promising results have focused the scientific research on the isolation and identification of the components responsible for the anticancer effects of scorpion venoms.

Peptides recognizing K^+^- and Na^+^-channels are prominent in scorpion venoms, constituting more than 75% of all peptide/proteins ([@B28]; [@B20]). Most peptides recognizing K^+^ channels are pore-blocking peptides and some of them have been studied in the context of cancer ([**Table 1**](#T1){ref-type="table"}). For example, KAaH1, a K~V~1.1 and K~V~1.3 blocker, and KAaH2, a K~V~1.1 blocker, both derived from the *Androctonus australis Hector* venom, have shown anticancer potential ([@B1]). KAaH1 inhibits migration and adhesion of different cancer cells, whereas KAaH2 inhibits the proliferation of gliomas ([@B1]). Evidence indicates that iberiotoxin inhibits cell proliferation, migration, and invasion in breast and endometrial cancer cell lines, due to its blocking effects on BK channels ([@B84]; [@B56]); while charybdotoxin, a known blocker of K~Ca~3.1, K~V~1.3, and BK channels, inhibits proliferation and cell cycle progression in pancreatic and endometrial cancer cell lines ([@B42]; [@B84]; [@B56]). Both toxins were isolated from the *Leiurus quinquestriatus* scorpion. Similarly, margatoxin (MgTX), a peptide isolated from *Centruroides margaritatus*, is a selective K~V~1.3-blocker that reduces cell proliferation, and tumor progression, decreases the expression of cell cycle regulators and increases the expression level of proapoptotic proteins in cancer experimental models ([@B43]). CsEKerg1 toxin, from the *Centruroides sculpturatus* scorpion has been evaluated as a hERG current inhibitor in an *in vitro* cancer model, suggesting its potential use in Kv11.1 channel-overexpressing cancer cells ([@B64]); this result opens a window of opportunity for other Kv11.1-blocking toxins described until now ([@B46]). κ-Hefutoxin 1 from *Heterometrus fulvipes* scorpion venom ([@B63]) has been identified as the first toxin recognizing K~V~10.1 channels, without affecting other voltage-gated K^+^-channels ([@B63]). Moreover, maurotoxin isolated from *Scorpio maurus palmatus* scorpion can block various potassium channels, including SK, IK, K~V~1.1, and K~V~1.3, some of which have been recognized as cancer-related ion channels ([@B13]). Tapamin, a toxin isolated from the *Mesobuthus tamulus* scorpion, can block some cancer-related ion channels, such as SK and K~Ca~3.1, and exerts a cytotoxic effect on cancer cells ([@B74]; [@B78]).

Although Na^+^-channel-modulating peptides represent the highest percentage among all scorpion venom-derived toxins ([@B20]), the identification of scorpion venom peptides that interact with metastatic-related Na^+^ channels has been difficult, and only three cases have been identified ([**Table 1**](#T1){ref-type="table"}). Cn2, a β-toxin from *Centruroides noxius Hoffmann* scorpion venom, modulates Na~V~1.6 activity in F11 neuroblastoma cells ([@B36]). In cell culture, Cn2 reduces proliferation by increasing cells at the SubG1 and G0/G1 stages, leading to apoptosis induction ([@B36]). This toxin binds to the receptor site 4, located in the S3--S4 and S1--S2 extracellular loops of the VGSC channel domain II, enhancing channel activation by shifting the voltage-dependence of channel activation to the left, as a consequence of voltage-sensor trapping ([@B16]), and reducing the Na^+^ current peak amplitude ([@B75]). AGAP, isolated from *Buthus martensii*, is an α-toxin that interacts with Na^+^-channels. Evidence suggests that AGAP affects the translation of the Na~V~β1 subunit in cancer cells and has been successfully evaluated against Ehrlich ascites tumor and S-180 fibrosarcoma models *in vivo*. Furthermore, this peptide can inhibit cancer cell stemness, epithelial-mesenchymal transition (EMT), migration, and invasion in MCF-7 and MDA-MB-231 human breast cancer cells *in vitro* and tumor growth *in vivo* ([@B40]; [@B47]). Finally, AaHIV toxin, isolated from *Androctonus australis* venom, is a Na^+^ channel-modulating toxin active against cancer cells ([@B7]). AaHIV can interact with the extracellular loops of segments S1--S2 in the voltage sensor domain, prolonging the inactivation recovery time of Nav1.6 channels, and inhibiting cancer cell proliferation in a dose-dependent manner ([@B7]). Unlike anti-migratory and anti-metastatic properties, the antiproliferative properties of Na^+^-channel-interacting scorpion toxins represent an unexpected feature that should be deeply investigated. There is no doubt that scorpion venom peptide toxins inhibit the functional activity of voltage-gated K^+^/Na^+^-channels, reducing their impact on the hallmark of cancer ([**Figure 1**](#f1){ref-type="fig"}).

It is worth mentioning that Chlorotoxin is the only toxin from scorpion venom that has been successfully evaluated in cancer preclinical and clinical trials ([@B22]; [@B60]; [@B21]). However, this toxin recognizes voltage-dependent Cl^-^ channels ([@B27]), which was not within the scope of this review.

Concluding Remarks {#s5}
==================

Evidence indicates that upregulation of voltage-dependent K^+^ and Na^+^ channels is linked to cancer hallmarks. Thus, they have become key player as new alternatives to be used as diagnostic, prognostic, and therapeutic targets in cancer. Scorpion venoms contain small peptides acting either at the cell membrane or intracellularly, and even cross the blood-brain barrier. The mechanisms of action of scorpion venom toxins described here, related to ion channel-modulating effects, give new insights to the plethora of potential new mechanisms of action that could be discovered from scorpion venom peptides. Laboratories dedicated to scorpion venom research have usually described the anticancer effects of scorpion venom and/or components for the first time; far away from the anticancer drug development programs and their resources. There is no doubt that the inclusion of these natural products, such as plant extracts, as part of the anticancer drug discovery programs, might increase the arsenal of active components as potential new drugs against relatively new targets. Importantly, the interaction of both research areas might represent a substantial qualitative leap that could open a highway of promising alternatives to be used as adjuvant therapeutic approaches or conventional treatment in anticancer therapy.
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